Citation: D. Mirchandani et F. Muggia, Re: Prognosis and treatment of patients with breast tumors of one centimeter or less and negative axillary lymph nodes, J NAT CANC, 93(18), 2001, pp. 1420-1421
Authors:
Demaria, S
Volm, MD
Shapiro, RL
Yee, HT
Oratz, R
Formenti, SC
Muggia, F
Symmans, WF
Citation: S. Demaria et al., Development of tumor-infiltrating lymphocytes in breast cancer after neoadjuvant paclitaxel chemotherapy, CLIN CANC R, 7(10), 2001, pp. 3025-3030
Authors:
Ferrari, AC
Chachoua, A
Singh, H
Rosenthal, M
Taneja, S
Bednar, M
Mandeli, J
Muggia, F
Citation: Ac. Ferrari et al., A phase I/II study of weekly paclitaxel and 3 days of high dose oral estramustine in patients with hormone-refractory prostate carcinoma, CANCER, 91(11), 2001, pp. 2039-2045
Authors:
Symmans, WF
Volm, MD
Shapiro, RL
Perkins, AB
Kim, AY
Demaria, S
Yee, HT
McMullen, H
Oratz, R
Klein, P
Formenti, SC
Muggia, F
Citation: Wf. Symmans et al., Paclitaxel-induced apoptosis and mitotic arrest assessed by serial fine-needle aspiration: Implications for early prediction of breast cancer response to neoadjuvant treatment, CLIN CANC R, 6(12), 2000, pp. 4610-4617
Authors:
Safra, T
Muggia, F
Jeffers, S
Tsao-Wei, DD
Groshen, S
Lyass, O
Henderson, R
Berry, G
Gabizon, A
Citation: T. Safra et al., Pegylated liposomal doxorubicin (doxil): Reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m(2), ANN ONCOL, 11(8), 2000, pp. 1029-1033